about
Influence of sildenafil on the anticonvulsant action of selected antiepileptic drugs against pentylenetetrazole-induced clonic seizures in mice.Effect of sildenafil on the activity of some antidepressant drugs and electroconvulsive shock treatment in the forced swim test in miceAnticonvulsant activity of melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, in mice.Clavulanic acid does not affect convulsions in acute seizure tests in mice.Antidepressant-like activity of sildenafil following acute and subchronic treatment in the forced swim test in mice: effects of restraint stress and monoamine depletion.SB 334867, a selective orexin receptor type 1 antagonist, elevates seizure threshold in mice.The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis.α-Spinasterol, a TRPV1 receptor antagonist, elevates the seizure threshold in three acute seizure tests in mice.Evaluation of the Anticonvulsant Effect of Brilliant Blue G, a Selective P2X7 Receptor Antagonist, in the iv PTZ-, Maximal Electroshock-, and 6 Hz-Induced Seizure Tests in MiceSildenafil, a phosphodiesterase type 5 inhibitor, enhances the activity of two atypical antidepressant drugs, mianserin and tianeptine, in the forced swim test in mice.Effect of sildenafil, a selective phosphodiesterase 5 inhibitor, on the anticonvulsant action of some antiepileptic drugs in the mouse 6-Hz psychomotor seizure model.Influence of sildenafil on the antidepressant activity of bupropion and venlafaxine in the forced swim test in mice.Evaluation of the antidepressant- and anxiolytic-like activity of α-spinasterol, a plant derivative with TRPV1 antagonistic effects, in mice.Evaluation of Anticonvulsant, Antidepressant-, and Anxiolytic-like Effects of an Aqueous Extract from Cultured Mycelia of the Lingzhi or Reishi Medicinal Mushroom Ganoderma lucidum (Higher Basidiomycetes) in Mice.Sildenafil, a phosphodiesterase type 5 inhibitor, reduces antidepressant-like activity of paroxetine in the forced swim test in mice.An anti-immobility effect of spermine in the forced swim test in mice.Effect of quercetin and rutin in some acute seizure models in mice.A new method to model electroconvulsive therapy in rats with increased construct validity and enhanced translational value.Acute anticonvulsant effects of capric acid in seizure tests in mice.Sildenafil influences the anticonvulsant activity of vigabatrin and gabapentin in the timed pentylenetetrazole infusion test in mice.Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice.Effect of Tadalafil on Seizure Threshold and Activity of Antiepileptic Drugs in Three Acute Seizure Tests in Mice.Increased seizure susceptibility and other toxicity symptoms following acute sulforaphane treatment in mice.Role of the adenosine system and glucose restriction in the acute anticonvulsant effect of caprylic acid in the 6 Hz psychomotor seizure test in mice.HBK-14 and HBK-15, triple 5-HT 1A , 5-HT 7 and 5-HT 3 antagonists with potent antidepressant- and anxiolytic-like properties, increase seizure threshold in various seizure tests in miceAnticonvulsant Activity of Pterostilbene in Zebrafish and Mouse Acute Seizure TestsSalvinorin A Does Not Affect Seizure Threshold in MiceKA-11, a Novel Pyrrolidine-2,5-dione Derived Broad-Spectrum Anticonvulsant: Its Antiepileptogenic, Antinociceptive Properties and in Vitro CharacterizationEvaluation of the role of different neurotransmission systems in the anticonvulsant action of sildenafil in the 6 Hz-induced psychomotor seizure threshold test in miceAcute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studiesEffect of Pterostilbene, a Natural Analog of Resveratrol, on the Activity of some Antiepileptic Drugs in the Acute Seizure Tests in MiceN-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug
P50
Q36106513-DF41EC4D-2EB4-4990-85D3-1BD52DD88DFBQ37693900-D346D13F-87FA-4E3D-BDC5-D39573593874Q39888015-2591A7DA-3DD1-4FCA-921B-5B84DCA16485Q40135754-50C3B1DF-A74E-4D7B-A69C-41B6362F6D80Q40709156-E996C80B-E874-44A5-B0DE-41D56AA8CCFCQ40886731-B019AD4A-0F7C-4DE6-8179-99844A83BA4EQ41435708-2792C5C5-3133-488B-9C01-FCD1D93769BDQ42046872-37340FA9-BB1B-45CC-BF4E-9635EC8F4020Q42727469-01D639DA-2CE2-41FA-A6E3-166E9D9EC06FQ44014551-848058EF-3B39-4DB1-97ED-1CB9FD5CD3E3Q46835634-B81DAC3F-A868-4876-9705-C64B2AC14197Q47197710-E0DA4FE0-FAA8-4489-925C-458D9F95D717Q47591674-835EDADB-352E-48FD-8A23-7A380C47B5BCQ47702968-6D63D488-EF80-457D-A619-174BDCE39D89Q48254496-A3FF6518-FE3E-407C-99E2-F0484C1DCC9DQ48277582-9C4AAF4A-2915-4EC6-9824-DFCA45728782Q48288346-25918EF1-5AD1-447F-8A5E-34DAA941F740Q48339104-B4B417A2-256D-4C1D-9E8B-E600DAD12EC3Q48438676-09C993BD-4613-4624-9F17-C3FA21D106B8Q48478480-6126D4C8-1D30-4E1C-AD18-8C84D974C1F8Q48735249-36FDA831-06A5-4074-8D23-71E23705D20BQ50088887-BECABA3A-BA8C-4EBE-A0D9-39D62FD5C394Q50443779-BD11AA19-A212-476E-B1F0-D2901794F81EQ51311783-EDEC7862-8A77-441C-93B1-8D3B2376F940Q63382951-88A5A50C-13DD-4D9B-B7A0-2F5CC95A75C3Q64234729-8D9C3726-0872-4E77-ABF7-204171F444C0Q90191903-E1B8AA38-3512-40CA-A643-1E0AE902112AQ91684841-7766C483-1A7B-411D-A312-D2DF4D203255Q91771685-9CA995D6-CB67-4189-BAFF-84465C6C5612Q92386219-F6B02619-C522-414F-8EAC-A10FCA76E0CBQ92406210-7D3920DD-D525-4DA3-A2D6-6721417A5974Q93113544-8456EAFD-8B32-45A9-A2AC-99D01CA5DF95
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Katarzyna Socała
@en
Katarzyna Socała
@nl
type
label
Katarzyna Socała
@en
Katarzyna Socała
@nl
prefLabel
Katarzyna Socała
@en
Katarzyna Socała
@nl
P31
P496
0000-0001-7706-2080